These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 22348829)

  • 1. The anti-EGFR antibody cetuximab sensitizes human head and neck squamous cell carcinoma cells to radiation in part through inhibiting radiation-induced upregulation of HIF-1α.
    Lu H; Liang K; Lu Y; Fan Z
    Cancer Lett; 2012 Sep; 322(1):78-85. PubMed ID: 22348829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Requirement of hypoxia-inducible factor-1alpha down-regulation in mediating the antitumor activity of the anti-epidermal growth factor receptor monoclonal antibody cetuximab.
    Li X; Lu Y; Liang K; Pan T; Mendelsohn J; Fan Z
    Mol Cancer Ther; 2008 May; 7(5):1207-17. PubMed ID: 18483308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha.
    Lu Y; Liang K; Li X; Fan Z
    Mol Cancer; 2007 Oct; 6():63. PubMed ID: 17931419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxia Mediates Differential Response to Anti-EGFR Therapy in HNSCC Cells.
    Wiechec E; Hansson KT; Alexandersson L; Jönsson JI; Roberg K
    Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28468237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual targeting of EGFR and focal adhesion kinase in 3D grown HNSCC cell cultures.
    Eke I; Cordes N
    Radiother Oncol; 2011 Jun; 99(3):279-86. PubMed ID: 21704406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cetuximab reverses the Warburg effect by inhibiting HIF-1-regulated LDH-A.
    Lu H; Li X; Luo Z; Liu J; Fan Z
    Mol Cancer Ther; 2013 Oct; 12(10):2187-99. PubMed ID: 23920275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dasatinib blocks cetuximab- and radiation-induced nuclear translocation of the epidermal growth factor receptor in head and neck squamous cell carcinoma.
    Li C; Iida M; Dunn EF; Wheeler DL
    Radiother Oncol; 2010 Nov; 97(2):330-7. PubMed ID: 20667610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1, 9-Pyrazoloanthrones downregulate HIF-1α and sensitize cancer cells to cetuximab-mediated anti-EGFR therapy.
    Lu Y; Li X; Lu H; Fan Z
    PLoS One; 2010 Dec; 5(12):e15823. PubMed ID: 21209911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer.
    Eke I; Zscheppang K; Dickreuter E; Hickmann L; Mazzeo E; Unger K; Krause M; Cordes N
    J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25663685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene status of head and neck squamous cell carcinoma cell lines and cetuximab-mediated biological activities.
    Kondo N; Tsukuda M; Taguchi T; Nakazaki K; Sakakibara A; Takahashi H; Toth G; Nishimura G
    Cancer Sci; 2011 Sep; 102(9):1717-23. PubMed ID: 21631644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor inhibition reduces angiogenesis via hypoxia-inducible factor-1α and Notch1 in head neck squamous cell carcinoma.
    Wang WM; Zhao ZL; Ma SR; Yu GT; Liu B; Zhang L; Zhang WF; Kulkarni AB; Sun ZJ; Zhao YF
    PLoS One; 2015; 10(2):e0119723. PubMed ID: 25723392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.
    Quesnelle KM; Wheeler SE; Ratay MK; Grandis JR
    Cancer Biol Ther; 2012 Aug; 13(10):935-45. PubMed ID: 22785204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression.
    Luwor RB; Lu Y; Li X; Mendelsohn J; Fan Z
    Oncogene; 2005 Jun; 24(27):4433-41. PubMed ID: 15806152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The inhibition of PARP but not EGFR results in the radiosensitization of HPV/p16-positive HNSCC cell lines.
    Güster JD; Weissleder SV; Busch CJ; Kriegs M; Petersen C; Knecht R; Dikomey E; Rieckmann T
    Radiother Oncol; 2014 Dec; 113(3):345-51. PubMed ID: 25467050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irradiation-induced regulation of plasminogen activator inhibitor type-1 and vascular endothelial growth factor in six human squamous cell carcinoma lines of the head and neck.
    Artman T; Schilling D; Gnann J; Molls M; Multhoff G; Bayer C
    Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):574-82. PubMed ID: 20117293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers.
    Herbst RS; Langer CJ
    Semin Oncol; 2002 Feb; 29(1 Suppl 4):27-36. PubMed ID: 11894011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquired resistance to cetuximab is associated with the overexpression of Ras family members and the loss of radiosensitization in head and neck cancer cells.
    Saki M; Toulany M; Rodemann HP
    Radiother Oncol; 2013 Sep; 108(3):473-8. PubMed ID: 23891090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Stat3 abrogates EGFR inhibitor resistance in cancer.
    Sen M; Joyce S; Panahandeh M; Li C; Thomas SM; Maxwell J; Wang L; Gooding WE; Johnson DE; Grandis JR
    Clin Cancer Res; 2012 Sep; 18(18):4986-96. PubMed ID: 22825581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiosensitization induced by the anti-epidermal growth factor receptor monoclonal antibodies cetuximab and nimotuzumab in A431 cells.
    González JE; Barquinero JF; Lee M; García O; Casaco A
    Cancer Biol Ther; 2012 Jan; 13(2):71-6. PubMed ID: 22231391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AMPK-mediated energy homeostasis and associated metabolic effects on cancer cell response and resistance to cetuximab.
    Li X; Lu Y; Lu H; Luo J; Hong Y; Fan Z
    Oncotarget; 2015 May; 6(13):11507-18. PubMed ID: 25871473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.